441768-86-1

Upstream product

• 441768-85-0 N-allyl-N-((1S,5R)-5-hydroxycyclopent-2-enyl)-4-methylbenzenesulfonamide 
• 320718-06-7 N-allyl-N-((1S,5R)-5-[tert-butyldimethylsilanyloxy)cyclopent-2-enyl]-4-methylbenzenesulfonamide 
• 320718-10-3 (S)-2-[(R)-1-(tert-butyldimethylsilanyloxy)but-3-enyl]-1-(toluene-4-sulfonyl)-2,5-dihydro-1H-pyrrole 
• 158361-26-3 N,N′-ditosyl-meso-cyclopent-4-ene-1,3-diol biscarbamate 
• 143668-59-1 N-((1S,5R)-5-hydroxycyclopent-2-enyl)-4-methylbenzenesulfonamide 
• 138604-24-7 (3aS,6aR)-3-(toluene-4-sulfonyl)-3,3a,6,6a-tetrahydrocyclopent-4-enoxazol-2-one 
• 4083-64-1 Tosyl isocyanate 
• 29783-26-4 cis-4-cyclopentene-1,3-diol 

Downstream Products

• 72741-87-8 swainsonine 

Relevant academic research and scientific papers

A new approach to (-)-swainsonine by ruthenium-catalyzed ring rearrangement

A new enantioselective synthesis of the idolizidine alkaloid (-)-swainsonine 1 in 40% overall yield starting from the known oxazolidinone 6 is described. Throughout the synthesis, the high efficiency of metal-catalyzed reactions is illustrated. The key step is a new ruthenium-catalyzed metathesis rearrangement reaction. In this ring-closing/ring-opening tandem process, stereocenters are transferred from a ring to the olefinic side chain of the formed heterocycle. The metathesis precursor was obtained by palladium-catalyzed desymmetrization of cyclopentenediol. The synthesis was completed by functionalization of the terminal double bond, cyclization of the second ring, and diastereoselective dihydroxylation.